The present invention relates to novel crystal forms of 4 {[4 ({[4 (2 2 2 trifluoroethoxy) 1 2 benzisoxazol 3 yl]oxy}methyl)piperidin 1 yl]methyl} tetrahydro 2H pyran 4 carboxylic acid. More particularly the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II) and to processes for the preparation of compositions containing and to uses of such polymorph forms.